Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada
The Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada objectively assesses the security and sustainability of Canada's immune globulin product supply
Canada faces a constant need for blood and plasma donations. Human plasma can be obtained from regular whole blood donations or through equipment that collects only plasma. Plasma is used to make a range of life-saving products such as immune globulin, a critical drug for treating Canadians who have immune deficiencies and other conditions.
Protecting the safety and security of Canada's blood supply, including plasma products, is a priority of Health Canada and its partners in the Canadian blood system: Canadian Blood Services, Héma-Québec and the provinces and territories.
Concerns have been raised about market conditions for immune globulin and the long-term sustainability of Canada's immune globulin supply. Health Canada established an expert panel to objectively assess these concerns and deliver a report to Health Canada before the end of March 2018.
A summary of the final report of the Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada, Protecting Access to Immune Globulins for Canadians, is available here. Should you wish to obtain a full copy of the report, please contact email@example.com.
Terms of Reference
The Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada was to:
- assess the long-term security and sustainability of Canada's immune globulin product supply,
- look at the potential impact on the Canadian blood supply should plasma collection be permitted to expand significantly in Canada, and
- examine emerging international practices and lessons learned that are relevant to the Canadian context.
Further details about the scope of the Panel's mandate are in the Terms of Reference.
Biographies of Panel Members
- Dr. Penny Ballem (Chair)
- Dr. Francine Décary (Deputy Chair)
- Dr. Patrick Robert (Special Advisor)
- Dr. Merlyn Sayers (Special Advisor)
A summary of Panel Member and Special Advisor affiliations and interests relevant to the Panel mandate as declared by panel members and special advisors is available. Health Canada considered these declarations as part of the appointment process. This summary is made available as part of Health Canada's commitment to
- Record of Decisions – March 27, 2018
- Record of Decisions – February 9, 2018
- Record of Decisions – December 7, 2017
- Record of Decisions – October 23-24, 2017
- Record of Decisions – September 12, 2017
- Record of Decisions – August 23, 2017
Report a problem or mistake on this page
- Date modified: